PURUSHOTHAM N SURAPANENI

Allopathic & Osteopathic Physicians|Internal Medicine RAMSEY, NJ NPI 1467401596

General Payments — all program years on this page

$4,347.51

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 169
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $688.32 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $688.3220

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $391.8523
2019 $1,681.8354
2020 $403.5312
2021 $644.3429
2022 $320.0316
2023 $217.6115
2024 $688.3220

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097396239 Novo Nordisk Inc $124.98 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104381391 AstraZeneca Pharmaceuticals LP $13.56 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104623786 AstraZeneca Pharmaceuticals LP $17.39 06/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104636849 AstraZeneca Pharmaceuticals LP $14.74 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104772306 AstraZeneca Pharmaceuticals LP $15.95 01/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105475953 AstraZeneca Pharmaceuticals LP $16.86 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105677319 AstraZeneca Pharmaceuticals LP $13.51 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106184675 ABBVIE INC. $3.68 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106184677 ABBVIE INC. $2.37 04/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106184679 ABBVIE INC. $125.00 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110773839 Eisai Inc. $16.43 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115769887 GlaxoSmithKline, LLC. $13.80 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116190130 GlaxoSmithKline, LLC. $10.25 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116262419 GlaxoSmithKline, LLC. $10.60 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116362793 GlaxoSmithKline, LLC. $120.83 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116378932 GlaxoSmithKline, LLC. $14.34 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116515399 GlaxoSmithKline, LLC. $110.81 12/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116686219 GlaxoSmithKline, LLC. $9.60 09/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151476590 Teva Pharmaceuticals USA, Inc. $18.95 09/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153670418 Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.67 10/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.